Prognostic markers for the definition of the individual metastatic risk in renal cell carcinoma are still missing. The aim of our study was to establish a total number of specific aberrations (TNSA) genetic score as a new prognostic test for metastatic risk evaluation. FISH was performed on isolated cell nuclei of 100 ccRCCs (50 M1/50 M0) and 100 FFPE sections (2nd cohort, 32 M1/68 M0). For each chromosomal region (1q21.3, 7q36.3, 9p21.3p24.1, 20q11.21q13.32) cut-off values were determined by ROC-curve analysis. TNSA was calculated based on the dichotomized specific CNVs. The prognostic significance of CNVs was proven by Cox and logistic regression. TNSA was the best predictor of metastasis and recurrence free survival in both cohorts. We derived an algorithm for risk stratification by combining TNSA and T-category, which increased the prognostic accuracy to 87% (specificity= 86%, sensitivity= 88%). This model divides patients into two risk groups with significantly different RFS, CSS and OS (p=3.8*10-5 , p=5*10-6 and p=3.57*10-8 respectively). The genetic risk model was superior to Leibovich score and was able to identify patients with metachronous metastatic spread which were incorrectly classified as "low" or "intermediate risk". We present a new tool for individual risk stratification by combining genetic alterations with clinico-pathologic parameters. Interphase FISH proves to be a dependable method for prognostic evaluation in primary tumor tissue on isolated cell nuclei as well as on FFPE sections. Especially in organ-confined tumors the genetic score seems to be an important tool to identify patients at high risk for metastatic disease. This article is protected by copyright. All rights reserved.
Genes, chromosomes & cancer. 2019 Mar 09 [Epub ahead of print]
Julia Grimm, Philip Zeuschner, Martin Janssen, Stefan Wagenpfeil, Arndt Hartmann, Christine Stöhr, Bastian Keck, Andreas Kahlmeyer, Michael Stöckle, Kerstin Junker
Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany., Institute of Medical Biometry, Epidemiology and Medical Informatics, Saarland University, Homburg, Germany., Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany., Department of Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.